Krystal Biotech Announces Third Quarter 2024 Financial Results and Provides Business Updates
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 10/22/2026
- Wall Street sinks as Nasdaq falls over 2% on AI cost worries
- Meta’s new Class C stock to keep Zuckerberg in California, fund AI spending spree
- Oil hits five-month high as Houthi attacks stoke supply fears
- Meta beats Q3 estimates, approves new nonvoting share class as AI spending surges
- Tesla stock up as automotive gross margin improves, free cash flow turns positive
Krystal Biotech (KRYS) PT Raised to $206 at Citi
November 4, 2024 4:42 PM ESTCiti analyst Carly Kenselaar raised the price target on Krystal Biotech (NASDAQ: KRYS) to $206.00 (from $204.00) while maintaining a Neutral rating.
The analyst comments "Though Vyjuvek sales of $83.8M were in-line vs. Citi/consensus of $82.3M/$83.4M, key risks associated with our... More



